Details
| Translated title of the contribution | Competition and rationalization in the German pharmaceutical market: An overview |
|---|---|
| Original language | German |
| Pages (from-to) | 163-181 |
| Number of pages | 19 |
| Journal | List Forum fur Wirtschafts- und Finanzpolitik |
| Volume | 39 |
| Issue number | 2 |
| Publication status | Published - 1 Jun 2013 |
| Externally published | Yes |
Abstract
This article discusses several regulations and their effects on rationalisation and competition in the German pharmaceutical market. On the one hand, the focus of the analysis lies on the new ways to determine refund amounts for new, innovative drugs directed through the “Act to Reorganize the Phamaceuticals’ Market in the German SHI System (AMNOG)”. In that part, the so-called ‘early benefit analysis’ and the ten first negotiated rebates play a big role. Furthermore, the early-benefit analysis may result into the grouping into an existing reference price group. To analyse the effects of that instrument on competition faced by the new drug, we also introduce three instruments that are important for generics (reference pricing, rebate contracts and copayment exemption levels). The analysis shows that many different regulations, mainly to reduce costs, exist in one market and may also influence each other. Furthermore, negotiation outcomes differ by the results of the early-benefit analysis and are also driven by the negotiators’ power.
ASJC Scopus subject areas
- Economics, Econometrics and Finance(all)
- Economics, Econometrics and Finance (miscellaneous)
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: List Forum fur Wirtschafts- und Finanzpolitik, Vol. 39, No. 2, 01.06.2013, p. 163-181.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Wettbewerb und Rationalisierung im deutschen Arzneimittelmarkt
T2 - Ein überblick
AU - Herr, Annika
PY - 2013/6/1
Y1 - 2013/6/1
N2 - This article discusses several regulations and their effects on rationalisation and competition in the German pharmaceutical market. On the one hand, the focus of the analysis lies on the new ways to determine refund amounts for new, innovative drugs directed through the “Act to Reorganize the Phamaceuticals’ Market in the German SHI System (AMNOG)”. In that part, the so-called ‘early benefit analysis’ and the ten first negotiated rebates play a big role. Furthermore, the early-benefit analysis may result into the grouping into an existing reference price group. To analyse the effects of that instrument on competition faced by the new drug, we also introduce three instruments that are important for generics (reference pricing, rebate contracts and copayment exemption levels). The analysis shows that many different regulations, mainly to reduce costs, exist in one market and may also influence each other. Furthermore, negotiation outcomes differ by the results of the early-benefit analysis and are also driven by the negotiators’ power.
AB - This article discusses several regulations and their effects on rationalisation and competition in the German pharmaceutical market. On the one hand, the focus of the analysis lies on the new ways to determine refund amounts for new, innovative drugs directed through the “Act to Reorganize the Phamaceuticals’ Market in the German SHI System (AMNOG)”. In that part, the so-called ‘early benefit analysis’ and the ten first negotiated rebates play a big role. Furthermore, the early-benefit analysis may result into the grouping into an existing reference price group. To analyse the effects of that instrument on competition faced by the new drug, we also introduce three instruments that are important for generics (reference pricing, rebate contracts and copayment exemption levels). The analysis shows that many different regulations, mainly to reduce costs, exist in one market and may also influence each other. Furthermore, negotiation outcomes differ by the results of the early-benefit analysis and are also driven by the negotiators’ power.
UR - http://www.scopus.com/inward/record.url?scp=85061921429&partnerID=8YFLogxK
U2 - 10.1007/BF03373047
DO - 10.1007/BF03373047
M3 - Artikel
AN - SCOPUS:85061921429
VL - 39
SP - 163
EP - 181
JO - List Forum fur Wirtschafts- und Finanzpolitik
JF - List Forum fur Wirtschafts- und Finanzpolitik
SN - 0937-0862
IS - 2
ER -